| 1 |
Tian XL, Suo BJ, Zhang H, Lu HP, Li CL, Zhang YX, Ren XL, Yao XY, Zhou LY, Song ZQ. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial. Helicobacter 2023;28:e12935. [PMID: 36374159 DOI: 10.1111/hel.12935] [Reference Citation Analysis]
|
| 2 |
Sadeghi H, Narimani T, Tabesh E, Shafiee F, Soltani R. Antibiotic resistance pattern of Helicobacter pylori strains isolated from patients in Isfahan, Iran. J Res Med Sci 2022;27:39. [PMID: 35968205 DOI: 10.4103/jrms.jrms_829_21] [Reference Citation Analysis]
|
| 3 |
Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran. J Chemother 2020;32:273-85. [PMID: 32657237 DOI: 10.1080/1120009X.2020.1790889] [Reference Citation Analysis]
|
| 4 |
Sebghatollahi V, Soheilipour M, Khodadoostan M, Shavakhi A, Shavakhi A. Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. Adv Biomed Res 2018;7:55. [PMID: 29657940 DOI: 10.4103/abr.abr_133_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 5 |
Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter Pylori in Iran: A Review. Middle East J Dig Dis 2018;10:5-17. [PMID: 29682242 DOI: 10.15171/mejdd.2017.84] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 6 |
Mansour-Ghanaei F, Joukar F, Naghipour MR, Forouhari A, Seyed Saadat SM. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication. World J Gastroenterol 2015; 21(2): 661-666 [PMID: 25593496 DOI: 10.3748/wjg.v21.i2.661] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 7 |
Fakheri H, Bari Z, Aarabi M, Malekzadeh R. Helicobacter pylori eradication in West Asia: A review. World J Gastroenterol 2014; 20(30): 10355-10367 [PMID: 25132752 DOI: 10.3748/wjg.v20.i30.10355] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Masoodi M, Panahian M, Rezadoost A, Heidari A. Eradication Rate of Helicobacter pylori using a Two-week Quadruple Therapy: A Report from Southern Iran. Middle East J Dig Dis 2013;5:81-5. [PMID: 24829674] [Reference Citation Analysis]
|
| 9 |
Minakari M, Davarpanah Jazi AH, Shavakhi A, Moghareabed N, Fatahi F. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter 2010;15:154-9. [PMID: 20402818 DOI: 10.1111/j.1523-5378.2009.00739.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 10 |
Dong J, Yu XF, Zou J. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: A meta-analysis. World J Gastroenterol 2009; 15(48): 6102-6110 [PMID: 20027685 DOI: 10.3748/wjg.15.6102] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
